Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 3619-3621 | ISSN: 2251-6719



Anaesthetic Management of a case of Hereditary spherocytosis posted for Laparoscopic Cholecystectomy and Splenectomy: A Case report:

Dr. Abirami Shanmugam^{1*}, Dr. Rathna Paramaswamy², Dr. Lakshmi R³

1. Postgraduate, Department of Anesthesiology, Saveetha Medical College, Chennai

2. Professor Department of Anesthesiology, Saveetha Medical College, Chennai

3. Professor and Head, Department of Anesthesiology, Saveetha Medical College, Chennai

*Corresponding author

Dr. Abirami Shanmugam, Postgraduate, Department of Anesthesiology, Saveetha Medical College, Chennai

(Received: 07 October 2023

Revised: 12 November

Accepted: 06 December)

ABSTRACT: KEYWORDS Hereditary Spherocytosis (HS), a non-immune hemolytic anemia, results from red blood Hereditary cell (RBC) transmembrane protein abnormalities. Surgical management, like laparoscopic Spherocytosis, cholecystectomy and splenectomy, poses challenges due to altered liver function and Anesthetic chronic hemolysis. A 20-year-old female with known HS underwent laparoscopic Management, cholecystectomy and splenectomy. Preoperative assessment revealed blood transfusion Laparoscopic history, altered liver function, and anemia. Examination showed pallor, icterus, and Cholecystectomy, hepatosplenomegaly. Laboratory findings indicated microcytic hyperchromic RBCs and Splenectomy, elevated bilirubin. Anesthetic management involved premedication, induction, and Hemolytic Anemia. intraoperative monitoring, with attention to hemodynamic stability. Anesthetic management in HS patients undergoing surgery requires understanding pathophysiology and complications. Multidisciplinary collaboration and meticulous perioperative care are essential for optimal outcomes.

1. INTRODUCTION

Hereditary spherocytosis (HS) is an extremely rare autosomal dominant family hemolytic disorder with significant clinical heterogeneity. features that vary from the absence of symptoms to fulminant hemolytic anemia. The estimated incidence in the Caucasian population ranges from 1:2000 to 1:5000 [1]. In HS, autosomal dominant inheritance accounts for 80% of instances; the remaining genes are either recessive or sporadic. It is characterized by the lack of two transmembrane proteins, spectrin and ankyrin, which attach the red blood cell bilayer to the membrane skeleton [2]. Aberrant spherocytes are sequestered and removed in hemolysis is caused by the spleen. These patients may have anemia, jaundice, splenomegaly, cholelithiasis, and altered liver function, which may affect how anesthetic medications are metabolized. This is because the spherocytes are susceptible to osmotic lysis [3]. This case presents a unique scenario of a young patient with Hereditary Spherocytosis undergoing laparoscopic cholecystectomy and splenectomy, complicated by a history of blood transfusion, altered liver function, and anemia.

CASE REPORT

A 20-year-old female with hereditary spherocytosis (HS) is scheduled for laparoscopic cholecystectomy and splenectomy. She has a history of blood transfusion, with a height of 157 cm and weight of 67 kg. Since 2014, she has been taking folic acid (0.5 mg OD). Additionally, she experienced jaundice two months ago. Preoperative evaluation reveals fair general condition with pallor and icterus, but no clubbing, cyanosis, or pedal edema. Vital signs are within normal limits, with a heart rate of 88 bpm, blood pressure of 120/80 mmHg, and oxygen saturation of 99% at room air. Airway assessment indicates adequate mouth opening, thyromental distance, and neck mobility, with no loose teeth or dental prostheses. Laboratory investigations show microcytic hyperchromic RBCs, elevated reticulocyte count, and positive osmotic fragility test consistent with HS. Imaging reveals cholelithiasis, splenomegaly (16 cm/13.7 cm/13 cm), and moderate hepatomegaly. NPO status is maintained for 8 hours preoperatively, with premedication consisting of pantoprazole (40 mg) and metoclopramide. Adequate blood and blood products are reserved, and two wide-bore IV lines are secured, with standard ASA monitoring in place. Preoxygenation with

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 3619-3621 | ISSN: 2251-6719



100% oxygen is performed, followed by premedication with IV glycopyrrolate (0.2 mg) and fentanyl (100 mcg). Anesthesia induction is achieved with IV thiopentone (100 mg) and succinylcholine (75 mg), and intubation is facilitated using a Macintosh blade 3 and ETT-7 tube.

Bilateral equal air entry is confirmed with ETCO2 trace, and a Ryles tube is inserted. Ventilation is initiated in VC mode, with muscle relaxation maintained using atracurium (initial dose of 20 mg and 5 mg boluses with TOF monitoring).

FIGURE 1: SPLEEN ENLARGEMENT IN CT SCAN



FIGURE 2: Spleenectomy intraoperative pic



FIGURE 3: Hemosiderotic spleen



A large spleen measuring 22 cm and gallbladder removed by meticulous surgical technique and intraoperative blood transfusion done due to significant blood loss of 400 ml. Postoperative analgesia was ensured by transverse abdominis plane block with 0.5% bupivacaine, providing effective pain relief. The intraoperative period lasted for 4 hours, during which 2 units of packed red blood cells (PRBC) were administered. Fluid balance was carefully monitored, with a total input of 2500 ml and an output of 900 ml. Intravenous medications, including paracetamol and ondansetron and fentanyl patch, were administered to

Journal of Chemical Health Risks

www.jchr.org

JCHR (2023) 13(6), 3619-3621 | ISSN: 2251-6719



manage pain and prevent postoperative nausea and vomiting. Upon completion of the procedure, the patient was successfully extubated awake after the reversal of neuromuscular blockade. This comprehensive perioperative management approach ensured the successful completion of the surgery and facilitated the patient's smooth recovery postoperatively.

2. DISCUSSION

Spherocytes in the peripheral circulation are linked to a heterogeneous form of hemolytic anemia called hereditary spherocytosis. In the past, HS was inherited autosomally dominantly, however some severe variants were inherited autosomally recessively.[4] Erythrocyte shape alterations in hemolytic anemia (HS) are attributed to abnormalities in the membrane protein spectrin, which lead to cytoskeleton instability and spherical red blood cells.

Rapid removal of splerocytic red blood cells from the bloodstream and their subsequent destruction by the spleen can result in anemia, jaundice, an enlarged spleen, and frequently gallstones. While mild cases of HS are typically found in young adults or even later in life, moderate cases can manifest as severe anemia and hyperbilirubinemia in infancy. In fact, diagnostic tests are frequently initiated in response to the discovery of gallstones in a young individual.

An increase in mean corpuscular hemoglobin concentration (MCHC), which is almost unique to hemoglobin-storage syndrome (HS), is one of its defining characteristics. Red cell morphology and aberrant osmotic fragility—a modified test known as the "pink test"—can typically be used to make the diagnosis. In certain instances, only molecular testing proving a mutation in one of the HS-causing genes can lead to a conclusive diagnosis.[5]

Haemolytic crisis, aplastic crisis, and megaloblastic crisis are the most often occurring HS problems. Children with HS are more likely to experience aplastic crises as a result of parvovirus and other infections because of their high RBC turnover and increased erythroid marrow activity. Heart failure, cardiovascular collapse, and severe anemia can potentially be fatal.[6] In cases with severe and moderate HS, folate medication is advised in order to avert megaloblastic crises.

Splenectomy is the surgical procedure used to cure the condition. It stops hemolysis, returns the hemoglobin level to normal, and eliminates jaundice. For every patient with splenomegaly, surgery is necessary to avoid the development of gallstones and hemolytic crisis. Patients who are asymptomatic and well-compensated might receive conservative care.[7]

The case demonstrates successful surgical management of laparoscopic cholecystectomy and splenectomy in a patient with Hereditary Spherocytosis (HS), showcasing effective multidisciplinary collaboration and meticulous anesthetic management. Despite the complexity of the procedure and the patient's medical history, the favorable postoperative outcome underscores the expertise of the healthcare team and the comprehensive care provided.

3. CONCLUSION

In conclusion, the case underscores the intricacies of managing Hereditary Spherocytosis (HS) patients during laparoscopic cholecystectomy and splenectomy, highlighting the need for tailored perioperative strategies. By navigating through challenges associated with chronic hemolysis and altered liver function, the successful outcome emphasizes the significance of individualized care and interdisciplinary collaboration in optimizing patient safety and well-being.

REFERENCES

- Anuradha M, Sonal M, Rochana B et al., Anesthetic considerations for patient of hereditary spherocytosis for splenectomy and cholecystectomy: A case report. Indian Journal of Basic and Applied Medical Research 2014;4(1):295-297.
- Sonal SK, Widya ST, Syed MK et al., Anesthetic management of a case with hereditary spherocytosis for splenectomy and open cholecystectomy. Medical journal of Dr. D.Y.Patil University 2016; 9(2):267-270.
- Sidhesh B, Vilas G, Merlyn D Anesthetic management of patient with hereditary spherocytosis for laparoscopic cholecystectomy and splenectomy. Saudi Journal of Anesthesia 2012;6(4):438-439.
- 4. Dacie J. The Haemolytic Anaemias. Vol. 86. London: Churchill Livingstone; 1995. pp. 4650–5.
- Grace RF, Lux SE. Disorders of the red cell membrane. In: Nathan and Oski's Hematology of Infancy and Childhood. 7th ed. Philadelphia: Saunders; 2009. pp. 659–837.
- Mariani M, Barcellini W, Vercellati C, Marcello AP, Fermo E, Pedotti P, et al. Clinical and hematologic features of 300 patients affected by hereditary spherocytosis grouped according to the type of the membrane protein defect. Haematologica. 2008;93:1310–7.
- Firkin F, Chesterman C, Penington D, Rush B. The hemolytic anaemias. In: De Gruchy's Clinical Haematology in Medical Practice. 5th ed. London: Blackwell Science; 1991. pp. 182–4.